Skip to content

Medline

US · MDLN #667 by market cap Listed 2025
37.04 -0.80 -2.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Fair Value how this is computed

Near fair value
33.20 fair value ≈ 58.24 83.27
  • Implied fair-value range of 33.20-83.27, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -36.4% below the average-multiple fair value of 58.24.

Valuation each multiple against its own 5-year range

P/B ratio 2.76 In line with history 52nd percentile
5-year average 2.71 · #28 of 51 in Medical Instruments & Supplies
P/E ratio 57.52 Expensive vs history 69th percentile
5-year average 40.81 · forward 22.07 · #22 of 27 in Medical Instruments & Supplies
P/S ratio 1.06 Cheap vs history 31st percentile
5-year average 1.14 · forward 0.98 · #8 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Medline (MDLN) 32.55B 57.52 2.76 0.00%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
West Pharmaceutical Services (WST) 27.19B 43.80 9.16 0.23%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value43.00 Economic moatNarrow UncertaintyMedium Capital allocationStandard

Trading 16.1% below Morningstar's fair value estimate.

Analyst note

Medline delivered 10% revenue growth and 12% adjusted EBITDA growth in its third quarter. Both figures were ahead of consensus estimates. The company lifted guidance for full-year organic sales growth by 50 basis points. Shares were up 15% intraday on Nov. 4.

Why it matters: Better-than-expected sales growth, driven by new customers and strong commercial execution, impressed us. More importantly, this momentum is not slowing, given the initial outlook for high-single-digit sales growth in 2027. Margin challenges continue to weigh on Medline, however. Though adjusted EBITDA margin was up 10 basis points in the quarter, it was still down 170 basis points in the first nine months. Inflationary pressures from elevated input costs worsened against last quarter, according to management, and headwinds look like they will continue into next year, given guidance for sales to outpace EBITDA in 2027. Since the introduction of 2026 guidance, the sales growth outlook has been raised 50 basis points sequentially for three consecutive quarters, but adjusted EBITDA guidance has either stayed flat or decreased. By our estimates, the full-year margin expectation has been lowered 150 basis points since February, to about 10.5% now. Next year's outlook implies the challenge will continue.

The bottom line: We maintain our $43 fair value estimate for narrow-moat Medline. Shares look roughly 10% undervalued after today's jump. Pricing actions can provide a quick fix for bottom-line pressure, but they have rarely been a meaningful lever for Medline. The firm appears to have limited ability in the near term to offset the challenging macro environment. However, our view of eventual margin recovery remains intact. We don't view this level of inflationary pressure as a headwind through the entirety of our five-year forecast period; we think mix improvements and Medline Brand conversion should eventually reverse the course.

Medline reiterated its midterm outlook for EBITDA growing at or above the sales growth rate. While recent results and near-term expectations deviate from this expectation, we still view this goal as achievable over the mid- and long term. New customer wins, which ended last year at $2.4 billion and are tracking well for $1 billion for 2026, afford Medline the opportunity to turn lower-margin businesses into higher-margin Medline Brand sales, underpinning our long-term margin recovery thesis. Management also noted a number of strategic initiatives, including extensive investments across supply chain networks and manufacturing facilities, which we think can help lower operating costs upon full implementation.

Fair value

We are reducing our fair value estimate to $43 per share from $48 after baking in the updated guidance and lowering near-term margin assumptions. Our valution reflects 17.5x EV/2026 adjusted EBITDA.

For fiscal 2026, we model 9.5% revenue growth from a mix of 6.0% Medline brand growth and 12.5% supply chain solutions growth. The firm had $2.3 billion in new customer signings during 2025, well ahead of its long-term target, and we expect a healthy level of brand conversion to Medline products throughout 2026 as these customers consolidate their med-surg distribution. We also think solid healthcare utilization will continue to drive end-market growth and Medline will benefit nicely as demand across its portfolio rises.

We model a higher adjusted EBITDA margin purely to account for tariff refunds; management expects the net benefit for the full year to be around $420 million. Excluding this impact, we think the base business margin will see headwinds from ongoing customer conversion efforts, elevated input costs from the Middle East conflicts, and expenses related to a facility fire. New prime vendor wins typically carry lower gross margins at inception, largely due to lower average selling prices across many Medline-branded products. As a result, we expect customer conversion to create additional near-term margin pressure.

Over the long term, we model 6.5% revenue growth and gradual margin expansion throughout our five-year forecast period. Macro secular trends like an aging population, increased healthcare expenditures, and rising prevalence of nonacute facilities should underpin the med-surg industry to grow at a mid-single-digit rate. We think Medline can outpace the market and gain share because it is well positioned across large integrated delivery networks as well as nonacute sites and has made efforts to expand its presence among fast-growing sectors like ambulatory surgery centers and home health facilities. Surgery volume in the US is poised to continue growing nicely, and we see demand for med-surg products to rise accordingly. We expect adjusted EBITDA margin to expand and reach above 12% by 2030. While initial customer conversions pressure gross margins, prime vendor contracts tend to improve profitability over time as Medline captures operating efficiencies through scale, logistics optimization, and vertical integration.

Economic moat

We assign Medline a narrow Morningstar economic moat rating because we believe the firm enjoys high switching costs that help generate excess returns above the weighted average cost of capital for at least the next 10 years.

Switching costs are particularly evident in Medline’s prime vendor relationships. In these relationships, Medline enters into long-term agreements (typically five years) to act as the primary consolidated logistics partner for medical-surgical product needs. This allows customers to consolidate med-surg purchases into a single source, capturing cost savings through volume discounts and operational efficiencies like inventory centralization and distribution integration. For Medline, this provides a predictable, resilient revenue stream. As of year-end 2024, Medline maintained over 1,300 prime vendor relationships, generating $16 billion in revenue—approximately 63% of total sales.

While initial contracts are only five years, customer loyalty is high, evidenced by a 98%-plus retention rate since 2020. Relationships also deepen over time through increased Medline-brand penetration. While Medline-branded products typically make up only a low-teens percentage of a customer's inventory at the start of a partnership, that figure typically climbs to 30%-40% by year 10. We believe the increasing adoption of Medline brands strengthens the mutual operational understanding between Medline and its customers, adding a layer of stickiness to their relationships. With the brand mix sitting at 35/65 (Medline versus national brands) at the end of 2025, significant runway remains for brand conversion.

Beyond initial agreements, many customers expand their partnerships from acute care into laboratories, outpatient, and post-acute facilities. We believe these multiyear, multisetting commitments demonstrate significant operational stickiness and expect this cross-segment expansion to be a key driver of future growth.

We think switching costs are lower for nonprime vendor relationship customers but still see signs of customer stickiness in those partnerships. Many items in Medline’s med-surg portfolio are highly commoditized, meaning customers could likely find a similar product from a competitor. Large GPOs have relationships with several med-surg providers/distributors, so multisourcing and individual product switches are common. That said, we think there are mild administrative switching costs between Medline and nonprime vendor customers, like understanding of needs, inventory management, and minor clinician preferences, that can sway purchasing patterns toward Medline over a competitor. Medline has over 2,300 dedicated sales representatives working directly with hospitals, doctors, and GPOs, roughly 1,000 more than McKesson and Cardinal and even more compared with smaller peers. This level of presence in the marketplace aids in understanding customer needs and improves distributor-customer relationships, ultimately leading to better customer retention and higher switching costs.

Bull case

Medline’s unrivaled scale in medical-surgical manufacturing and distribution enables the firm to enjoy long-term secular trends like an aging population and increased prevalence of chronic conditions.

Medline’s vertical integration leads to significant operational leverage and efficiency, leading to margin expansion.

The prime vendor model is a key competitive advantage for Medline. Winning new contracts affords Medline further opportunities in wallet penetration, share gains, and ultimately durable long-term revenue generation.

Bear case

Continued consolidation in the healthcare sector affords more buying power to large hospitals and GPOs and could lead to Medline conceding price and contracting margins.

The regulatory framework around healthcare and insurance can be dynamic. Any downward risks in healthcare utilization could curb spending from Medline’s key customers, threatening Medline’s growth.

After decades of operating as a private entity, a transformation into a public company could come with increased operational pressures and additional capital allocation priorities.

By Keonhee Kim

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Medline discussion 0 comments

Add a comment